IsoRay, Inc. (ISR) EPS Estimated At $-0.03

September 8, 2018 - By Lisa Delgado

IsoRay, Inc. (NYSEAMERICAN:ISR) LogoInvestors sentiment decreased to 1.4 in Q1 2018. Its down 7.60, from 9 in 2017Q4. It turned negative, as 2 investors sold IsoRay, Inc. shares while 3 reduced holdings. 3 funds opened positions while 4 raised stakes. 3.82 million shares or 49.37% less from 7.55 million shares in 2017Q4 were reported.
Auxier Asset Mgmt owns 14,218 shares. Blackrock reported 867,114 shares. Citadel has invested 0% of its portfolio in IsoRay, Inc. (NYSEAMERICAN:ISR). The California-based Wells Fargo And Mn has invested 0% in IsoRay, Inc. (NYSEAMERICAN:ISR). 5,000 were reported by Jnba Advisors. Geode Cap Mgmt Llc owns 269,778 shares. 1.51M were accumulated by Vanguard. Northern Tru Corporation reported 124,577 shares or 0% of all its holdings. Utd Services Automobile Association reported 15,938 shares. Atlantic Tru Gp Limited Company owns 0% invested in IsoRay, Inc. (NYSEAMERICAN:ISR) for 5,300 shares. Bancshares Of America De invested 0% in IsoRay, Inc. (NYSEAMERICAN:ISR). Susquehanna Limited Liability Partnership invested in 0% or 326,548 shares. Morgan Stanley reported 1,473 shares. Commercial Bank Of Ny Mellon has invested 0% in IsoRay, Inc. (NYSEAMERICAN:ISR). Raymond James Financial Services Inc reported 0% stake.

Analysts expect IsoRay, Inc. (NYSEAMERICAN:ISR) to report $-0.03 EPS on September, 27.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.03 EPS. After having $-0.02 EPS previously, IsoRay, Inc.’s analysts see 50.00 % EPS growth. The stock decreased 4.19% or $0.0232 during the last trading session, reaching $0.5299. About 673,609 shares traded. IsoRay, Inc. (NYSEAMERICAN:ISR) has declined 9.55% since September 8, 2017 and is downtrending. It has underperformed by 22.12% the S&P500.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, makes, and sells isotope medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company has market cap of $35.68 million. The firm produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It currently has negative earnings. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed.

IsoRay, Inc. (NYSEAMERICAN:ISR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.